Here, we highlighted the rationale of genetic modifications for glaucoma therapies either as the gene therapy targets or cell replacement therapy to provide long-term neurotrophin therapeutics on-site using new generations of safer and more efficient DNA vectors and modern genetic modification techniques. The gene discussed is BDNF; the disease is glaucoma.